SERM and 5α-Reductase Inhibitor Compositions for Hormone Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormone replacement therapies for menopausal symptoms and aging-related diseases face challenges due to unclear cardiovascular outcomes and side effects, particularly with estrogen and androgen therapies, which do not adequately address the broader safety issues and risk factors for the growing aging population.
Innovation Solution
The development of compositions combining selective estrogen receptor modulators (SERMs) and 5α-reductase inhibitors, or selective androgen receptor modulators (SARMs) with estrogen receptor modulators, to modulate hormone activity and mitigate cardiovascular risks, while stimulating endogenous testosterone production, thereby offering a safer and more effective hormone replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If estrogen replacement therapy is used to treat menopausal symptoms and prevent aging-related diseases, then benefits are achieved in CNS (reduction of hot flashes), bone (prevention of osteoporosis), breasts (prevention of breast cancer), and vagina (reduction in vaginal atrophy), but risks increase in uterus (increase cancer incidence) and cardiovascular system (increase of blood clots)
Solution Approach 1:
The patent segments the estrogen receptor modulation into tissue-specific actions by combining SERMs (which provide tissue-selective agonist/antagonist effects) with estrogen therapy. This allows beneficial effects in target tissues while minimizing harmful effects in cardiovascular and uterine tissues.
Solution Approach 2:
The patent uses SERMs as intermediary compounds that mediate between estrogen therapy and target tissues. SERMs selectively modulate estrogen receptor activity in different tissues, acting as a bridge to achieve therapeutic benefits while blocking harmful cardiovascular and uterine effects.
2Object-affected harmful factors
If progestin is combined with estrogens to counter the uterus effect, then uterine cancer risk is reduced, but beneficial effects on breasts are counteracted and negative cardiovascular effects are added
Solution Approach 1:
Instead of adding progestin to counter uterine effects (which creates new problems), the patent inverts the approach by using SERMs to selectively block uterine estrogen receptor activity while maintaining beneficial effects in other tissues. This reverses the traditional problem-solving sequence.
Solution Approach 2:
The patent applies local quality by using SERMs with different tissue-selective profiles. The SERM component provides antagonist activity in the uterus while maintaining agonist activity in beneficial tissues like bone and brain, creating locally differentiated therapeutic effects.
3Object-affected harmful factors
If SERMs are used to avoid negative uterus effect, then uterine cancer risk is reduced, but beneficial effects on CNS are lost
Solution Approach 1:
The patent merges SERM therapy with estrogen therapy to combine the advantages of both approaches. The SERM component provides uterine protection while the estrogen component provides CNS benefits, achieving both goals simultaneously through combination therapy.
Data Source
AI summary
Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.